US Food and Drug Administration approval comes a week after European heart experts endorsed the longer-term use of Brilinta

AstraZeneca received a much-needed boost when its blood-thinning drug, Brilinta, a potential blockbuster, was approved by the US health regulator for wider use.

The Food and Drug Administration approved Brilinta tablets for longer-term use in patients with a history of heart attack. The new 60mg dose can be taken twice a day along with aspirin beyond a year after a heart attack. Until now, the blood thinner could only be prescribed for one year after a heart attack, as a 90mg dose.

Continue reading…
Source: The Guardian Circular Economy RSS